Navigation

2007/055 NICE appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis


The National Institute for Health and Clinical Excellence (NICE) has today (24 October) published final guidance on the use of the tumour necrosis factor alpha (TNF-α) inhibitors adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis.

This page was last updated: 05 November 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright @ 2012 National Institute for Health and Clinical Excellence. All rights reserved.